The Marketing Sentinal article is just an auto bot...
That article was just fed into an algorithm and nothing behind it...I see them all the time for emerging microcap stocks.
All of Avalon's fundamentals are still solidly in place. Dr. Tran from BioScience Capital Partners still loves AVCO:
"Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.
Leveraging precision medicine, Avalon employs liquid biopsy with exosomes biomarkers to provide an accurate diagnosis for various cancers and even nonalcoholic steatohepatitis.
The crown jewel of the immunotherapy franchise is a premier multi-target CAR-T. It has the power to circumvent prior limitations of the first generation drugs (Yescarta and Kymriah).
Remarkably, Avalon is cutting into the gargantuan regenerative medicine market as it harnesses the power of stem cell-derived exosomes.
With unique infrastructure and research programs, Avalon is positioned for colossal growth ahead. The financials and valuation indicate highly asymmetric rewards to risks profile."
We also now have the possibility of both rapid Covid-19 testing and also a possible Covid vaccine. But this is NOT a Covid-19 play but if they do develop so be it..
I like the fact that management has skin in the game with a millionaire business man on the board along with a medically savvy CEO who both own thousands of shares. They are going to do whatever it takes to make Avalon successful.
Avalon is also working with MIT, Cornell University, GE Health and other prestigious organizations overseas in Europe and China...Organizations like this don't just work with anybody...
The share structure for this stock is solid with only 80 million Outstanding Shares...very reasonable.
I don't know Vipyr...but I like our chances with this one and now even more so by scooping up shares at such a low price today...
That article was just fed into an algorithm and nothing behind it...I see them all the time for emerging microcap stocks.
All of Avalon's fundamentals are still solidly in place. Dr. Tran from BioScience Capital Partners still loves AVCO:
"Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.
Leveraging precision medicine, Avalon employs liquid biopsy with exosomes biomarkers to provide an accurate diagnosis for various cancers and even nonalcoholic steatohepatitis.
The crown jewel of the immunotherapy franchise is a premier multi-target CAR-T. It has the power to circumvent prior limitations of the first generation drugs (Yescarta and Kymriah).
Remarkably, Avalon is cutting into the gargantuan regenerative medicine market as it harnesses the power of stem cell-derived exosomes.
With unique infrastructure and research programs, Avalon is positioned for colossal growth ahead. The financials and valuation indicate highly asymmetric rewards to risks profile."
We also now have the possibility of both rapid Covid-19 testing and also a possible Covid vaccine. But this is NOT a Covid-19 play but if they do develop so be it..
I like the fact that management has skin in the game with a millionaire business man on the board along with a medically savvy CEO who both own thousands of shares. They are going to do whatever it takes to make Avalon successful.
Avalon is also working with MIT, Cornell University, GE Health and other prestigious organizations overseas in Europe and China...Organizations like this don't just work with anybody...
The share structure for this stock is solid with only 80 million Outstanding Shares...very reasonable.
I don't know Vipyr...but I like our chances with this one and now even more so by scooping up shares at such a low price today...
"It never was my thinking that made the big money for me. It always was the sitting. Got that? My sitting tight!" - Reminiscences of a Stock Operator -
Recent ALBT News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 03:02:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:00:48 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/21/2026 08:30:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:30:24 PM
- Avalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform Development • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/20/2026 09:10:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/17/2026 09:23:22 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/17/2026 09:23:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:10:31 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/08/2026 09:19:26 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 04/08/2026 09:04:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/02/2026 08:27:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:10:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 12:30:07 PM
- Avalon Quantum AI Announces Strategic Collaboration with Caylent, an Amazon Web Services Premier Tier Partner, to Advance its Catch-Up Product into a Fully Autonomous Agentic AI Video Platform • GlobeNewswire Inc. • 03/31/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:36:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:35:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/24/2026 09:06:36 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/05/2026 10:20:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/02/2026 09:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:53:12 PM
- Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules • GlobeNewswire Inc. • 02/27/2026 10:30:26 PM
